p53 functional activation is independent of its genotype in five esophageal squamous cell carcinoma cell lines

Frontiers of Medicine in China

Volumn 4, Issue 4, 2010, Pages 412-418

  Ji, Junfang ^a   Wu, Kun ^a   Wu, Min ^a   Zhan, Qimin ^a  

^a CANCER HOSPITAL   (China)

Author keywords

DNA damage; esophageal squamous cell carcinoma; p53

Indexed keywords

PROTEIN P53;

ARTICLE; BIOSYNTHESIS; DNA DAMAGE; ESOPHAGUS TUMOR; GENETICS; GENOTYPE; HUMAN; MUTATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TRANSCRIPTION INITIATION; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DNA DAMAGE; ESOPHAGEAL NEOPLASMS; GENES, P53; GENOTYPE; HUMANS; MUTATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 78650701058     PISSN: 16737342     EISSN: 16737458     Source Type: Journal    
DOI: 10.1007/s11684-010-0260-x     Document Type: Article

References (26)

1. Parkin D M, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin, 2005, 55(2): 74-108.
2. Ke L. Mortality and incidence trends from esophagus cancer in selected geographic areas of China circa 1970-90. Int J Cancer, 2002, 102(3): 271-274.
3. Lerut T, Coosemans W, De Leyn P, van Raemdonck D, Deneffe G, Decker G. Treatment of esophageal carcinoma. Chest, 1999, 116(6 Suppl): 463S-465S.
4. Zhan Q, Carrier F, Fornace A J Jr. Induction of cellular p53 activity by DNA-damaging agents and growth arrest. Mol Cell Biol, 1993, 13(7): 4242-4250.
5. Hainaut P, Hernandez T, Robinson A, Rodriguez-Tome P, Flores T, Hollstein M, Harris C C, Montesano R. IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools. Nucleic Acids Res, 1998, 26(1): 205-213.
6. May P, May E. Twenty years of p53 research: structural and functional aspects of the p53 protein. Oncogene, 1999, 18(53): 7621-7636.
7. Zhan Q, Fan S, Bae I, Guillouf C, Liebermann D A, O'Connor P M, Fornace A J Jr. Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene, 1994, 9(12): 3743-3751.
8. Greenblatt MS, Bennett WP, Hollstein M, Harris C C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res, 1994, 54(18): 4855-4878.
9. Tanaka H, Shibagaki I, Shimada Y, Wagata T, Imamura M, Ishizaki K. Characterization of p53 gene mutations in esophageal squamous cell carcinoma cell lines: increased frequency and different spectrum of mutations from primary tumors. Int J Cancer, 1996, 65(3): 372-376.
10. Ko L J, Prives C. p53: puzzle and paradigm. Genes Dev, 1996, 10(9): 1054-1072.
11. Merchant A K, Loney T L, Maybaum J. Expression of wild-type p53 stimulates an increase in both Bax and Bcl-xL protein content in HT29 cells. Oncogene, 1996, 13(12): 2631-2637.
12. Miyashita T, Krajewski S, Krajewska M, Wang H G, Lin H K, Liebermann D A, Hoffman B, Reed J C. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene, 1994, 9(6): 1799-1805.
13. Pietenpol J A, Tokino T, Thiagalingam S, el-Deiry W S, Kinzler K W, Vogelstein B. Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc Natl Acad Sci U S A, 1994, 91(6): 1998-2002.
14. Moll U M, LaQuaglia M, Bénard J, Riou G. Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc Natl Acad Sci U S A, 1995, 92(10): 4407-4411.
15. Moll U M, Ostermeyer A G, Haladay R, Winkfield B, Frazier M, Zambetti G. Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage. Mol Cell Biol, 1996, 16(3): 1126-1137.
16. Fan W, Jin S, Tong T, Zhao H, Fan F, Antinore M J, Rajasekaran B, Wu M, Zhan Q. BRCA1 regulates GADD45 through its interactions with the OCT-1 and CAAT motifs. J Biol Chem, 2002, 277(10): 8061-8067.
17. Barnas C, Martel-Planche G, Furukawa Y, Hollstein M, Montesano R, Hainaut P. Inactivation of the p53 protein in cell lines derived from human esophageal cancers. Int J Cancer, 1997, 71(1): 79-87.
18. Fujii T, Kato S, Yamana H, Tanaka Y, Fujita H, Shirouzu K, Morimatsu M. Expression of G1 cell cycle markers and the effect of adenovirus-mediated overexpression of p21Waf-1 in squamous cell carcinoma of the esophagus. Int J Oncol, 2001, 18(1): 157-163.
19. Rigberg D A, Centeno J, Kim F S, Ke B, Swenson K, Maggard M, McFadden D W. Irradiation-induced up-regulation of Fas in esophageal squamous cell carcinoma is not accompanied by Fas ligand-mediated apoptosis. J Surg Oncol, 1999, 71(2): 91-96.
20. el-Deiry W S. Regulation of p53 downstream genes. Semin Cancer Biol, 1998, 8(5): 345-357.
21. Leng R P, Lin Y, Ma W, Wu H, Lemmers B, Chung S, Parant J M, Lozano G, Hakem R, Benchimol S. Pirh2, a p53-induced ubiquitinprotein ligase, promotes p53 degradation. Cell, 2003, 112(6): 779-791.
22. Zhan Q. Gadd45a, a p53- and BRCA1-regulated stress protein, in cellular response to DNA damage. Mutat Res, 2005, 569(1-2): 133-143.
23. Rigberg D A, Kim F S, Blinman T A, Cole M A, Lane J S, So J, McFadden D W. p21 expression is increased by irradiation in esophageal squamous cell carcinoma. J Surg Res, 1998, 76(2): 137-142.
24. el-Deiry W S, Kern S E, Pietenpol J A, Kinzler K W, Vogelstein B. Definition of a consensus binding site for p53. Nat Genet, 1992, 1(1): 45-49.
25. Hollstein M, Sidransky D, Vogelstein B, Harris C C. p53 mutations in human cancers. Science, 1991, 253(5015): 49-53.
26. Liang S H, Clarke M F. Regulation of p53 localization. Eur J Biochem, 2001, 268(10): 2779-2783.